Ikena Oncology Announces New Cancer Program, Shelves Early Asset For Colorectal Cancer
- Ikena Oncology Inc nominated a next-generation mitogen-activated protein kinase (MEK)-RAF complex inhibitor, IK-595, as its first development candidate in the RAS pathway.
- The company plans to submit an investigational new drug application (IND) for IK-595 to the FDA in the second half of 2023.
- The company's paralog-selective TEAD inhibitor IK-930 is advancing as planned in dose escalation. Monotherapy clinical data is expected in 2H 2023.
- Preclinical data on differentiation and advantages of paralog selectivity are planned for presentation in the first half of 2023.
- Following a portfolio review, the company is discontinuing the internal clinical development of the EP4 antagonist IK-007 and exploring strategic alternatives for this program.
- Portfolio reprioritization and streamlining of discovery and clinical activities contribute to extending the cash runway into 2025.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.